Specifically, that could include a ban on spread pricing – when a PBM reimburses pharmacies one price for a medicine, but ...

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for ...

Recruiting for clinical trials is hard… and expensive. And a large component of that time involves people sifting through ...

Its rare disease pipeline includes sickle cell disease therapy etavopivat, currently in the phase 2/3 HIBISCUS trial due to ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...

In a time when pharmaceutical companies no longer have the economic luxury of decades-long development cycles, indication ...